Business Context and Reporting Period
This Form 6-K filing by Hutchison China MediTech Limited (HUTCHMED) covers the month of April 2019. The primary purpose of the filing is to disclose supplemental information regarding a proposed listing of the Company's ordinary shares on the Main Board of the Stock Exchange of Hong Kong Limited (SEHK). The filing details a proposed share split (1-for-10) and amendments to the Articles of Association. The financial data presented is unaudited and reflects the Company's position as of February 28, 2019, with comparative data for prior years ending December 31.
Key Financial Metrics
Liquidity and Assets (as of February 28, 2019):
- Net Current Assets: US$265.4 million (decreased from US$285.1 million as of December 31, 2018).
- Cash and Cash Equivalents: US$69.9 million.
- Short-term Investments: US$212.2 million.
- Total Current Assets: US$361.1 million.
- Total Current Liabilities: US$95.7 million.
Debt and Indebtedness (as of February 28, 2019):
- Total Indebtedness: US$33.3 million (all unsecured and unguaranteed).
- Bank Borrowings (Non-current): US$26.8 million.
- Lease Liabilities: US$5.9 million (combined current and non-current).
- Maturity Profile: US$3.0 million due within one year; US$29.3 million due in one to two years.
Key Financial Ratios (as of December 31, 2018):
- Current Ratio: 433%.
- Quick Ratio: 419%.
Revenue and Profit: The filing text does not provide specific revenue, profit, or cash flow figures for the period ending February 28, 2019, or for the year ended December 31, 2018. It only references customer concentration percentages.
Material Changes
Net Current Assets: Net current assets decreased by approximately US$19.7 million from December 31, 2018, to February 28, 2019. The Company attributes this decline primarily to continued investment in research and development activities.
Liquidity Ratios: The current and quick ratios have remained strong and stable, increasing slightly from 413% and 402% respectively in 2017 to 433% and 419% in 2018, driven by cash and short-term investment levels following a 2017 follow-on offering.
Customer Concentration: Revenue from the five largest customers increased to 35% of total revenue in 2018, up from 27% in 2017 and 26% in 2016. The largest single customer accounted for 11% of revenue in 2018.
Guidance, Outlook, Risks, and Unusual Items
Proposed Listing and Share Split: The Company intends to list on the SEHK Main Board. Concurrently, it plans a 1-for-10 share split and an adjustment to the American Depositary Share (ADS) ratio from 1:0.5 to 1:5 to maintain the ADS trading price. There is no assurance as to if or when the listing will occur.
Risk Factors:
- Scientific Data Transfer: New Chinese regulations (Scientific Data Measures) may restrict the transfer of scientific data abroad, potentially hindering R&D and clinical trial reporting if government approvals are delayed or denied.
- Legal and Litigation: The Company faces potential litigation risks that could be costly and divert management attention.
- Shareholder Rights: As a Cayman Islands company, shareholders may have fewer rights and face greater difficulty in enforcing claims compared to jurisdictions like the U.S., U.K., or Hong Kong. Enforcement of judgments against assets in China may also be difficult.
Unusual Items: The financial data as of February 28, 2019, is unaudited. The Company's independent registered public accounting firm has not performed any procedures on this specific data.
Investor Verification Checklist
- Verify the status and timeline of the proposed SEHK listing and the shareholder approval for the share split.
- Confirm the impact of the "Scientific Data Measures" on the Company's ability to transfer clinical trial data from China to international partners.
- Review the full audited financial statements for the year ended December 31, 2018, to obtain missing revenue and profit metrics not included in this summary.
- Assess the concentration risk associated with the top five customers representing 35% of 2018 revenue.
- Monitor the maturity profile of debt, noting that approximately US$29.3 million is due within two years.